(St. Louis, MO) –September 8, 2016, GeneriCo, LLC, a global specialty generic pharmaceutical company, has announced the signing of a collaboration with Zhejiang Hisun Pharmaceutical Co, Ltd, and its affiliate Hisun Pharmaceuticals USA, whereby GeneriCo will be the exclusive sales and marketing partner for a portfolio of generic drugs developed and manufactured by Hisun for the US market. As part of the terms, subject to full final agreement, GeneriCo is planning to launch these products during 2016 and 2017.
“This collaboration is a landmark for GeneriCo as it allows us to extend and enhance our commercialization programs ahead of our internally developed generic product launches,” said Tom Brya, President & CEO of GeneriCo.
Shu Zhu, Board Member and Head of Product and Partner Selection at GeneriCo, noted; “This reinforces GeneriCo’s ongoing effort to bring value driven generic products to the U.S. market via our innovative collaboration model, and in alignment with our global view to the industry.”
GeneriCo is a generic pharmaceutical company focused on developing and marketing niche, high barrier drugs in the U.S. utilizing its proprietary data-driven, algorithm-based product selection process. The Company employs a four-pillar collaboration business strategy capitalizing on management’s deep industry knowledge and experience to collaborate with partners on the discovery, formulation, development and manufacture of generic drugs. The Company expects its 1st internally-developed ANDA to be filed in early 2017, with a total of 4 ANDAs filed by the end of 2017.
GeneriCo is led by a management team with 195 years of combined experience in formulation, manufacturing and commercial leadership. The team has successfully filed and launched over 200 generic drugs and created more than $30B of firm value.
Zhejiang Hisun Pharmaceuticals Co. Ltd, is a fully integrated pharmaceutical company focusing on a broad range of products and services for the benefit of all who use them. Headquartered in Taizhou Zhejiang China, Hisun is a leading Active Pharmaceutical Ingredient supplier and a top global API exporter in China. Hisun produces a wide range of finished dosage pharmaceuticals including capsule, tablet and injectable forms. The current drug portfolio includes more than 70 products across a broad array of therapeutic areas. Hisun is an innovation leader in the area of biopharmaceuticals. In July 2015, Hisun launched its first biosimilar product for the China market – Recombinant Human Tumor Necrosis Factor-α Receptor II:IgG Fc Fusion Protein for Injection. The company’s wholly owned subsidiary, Hisun Pharmaceuticals USA, is an emerging specialty pharmaceutical company located in Princeton, NJ. With over 20 ANDAs filed with the FDA, Hisun is building a diverse portfolio of specialty generic pharmaceuticals for the US market. For more information, visit www.Hisunpharm.com.
For more information, please visit www.genericopharma.com
Deborah Knobelman, PhD – Chief Financial Officer Phone Number: +1.646.221.5830